Nucleotide excision repair pathway review I: Implications in ovarian cancer and platinum sensitivity
- 31 October 2007
- journal article
- review article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 107 (1), S56-S71
- https://doi.org/10.1016/j.ygyno.2007.07.043
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- Nucleotide Excision RepairProgress in Nucleic Acid Research and Molecular Biology, 2005
- Treatment goals in ovarian cancerInternational Journal of Gynecologic Cancer, 2005
- Cancer of the OvaryThe New England Journal of Medicine, 2004
- How nucleotide excision repair protects against cancerNature Reviews Cancer, 2001
- Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapyCancer Treatment Reviews, 1998
- Carboplatin versus cisplatin in solid tumors: An analysis of the literatureAnnals Of Oncology, 1998
- Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patientsAnnals of Oncology, 1997
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Clinical Reversal of Drug Resistance in Ovarian CancerGynecologic Oncology, 1993
- The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove.Proceedings of the National Academy of Sciences of the United States of America, 1988